Goldman Sachs Maintains Buy on Relmada Therapeutics, Raises Price Target to $81

Goldman Sachs analyst Andrea Tan maintains Relmada Therapeutics (NASDAQ:RLMD) with a Buy and raises the price target from $49 to $81.

Goldman Sachs analyst Andrea Tan maintains Relmada Therapeutics (NASDAQ:RLMD) with a Buy and raises the price target from $49 to $81.

Total
0
Shares
Related Posts